Worldwide, Total Mesorectal Excision (TME) has become the gold standard treatment for middle and lower rectal cancer. Studies have demonstrated a TME improves local recurrence rates and the corresponding survival by as much as 20%. High-quality TME surgery reduces local recurrence from 20% to 30% and increases 5-year survival from 48% to 68%. The June 2022 CTR Coding Break titled ‘STORE Manual 2022 Macroscopic Mesorectum’ discusses…
The May 2022 CTR Coding Break titled First Course vs Subsequent Treatment discusses first course and second course treatment standard setter definitions, the differences between the two courses as well as a few case examples. First course treatment is the initial plan of treatment, includes any modality of treatment and may last a year or more. First course treatment has an ending point with different scenarios…
This month Registry Partners is celebrating its 20 year anniversary! In May of 2002, Registry Partners was founded with a vision of reducing the cost of registry operations through remote registry support, providing hospital access to registry expertise outside of geographic barriers, and defining a delivery model to support the highest quality data collection in the industry. And now, 20 years later, we celebrate how far…
Our newest video for the May 2022 edition of Sepsis Chatter is titled: “Sepsis Chatter- Initial Lactate Collection & Results and Repeat Lactate Collection”. This presentation begins with an overview of the rationale for collecting lactate levels in patients with sepsis, severe sepsis, and septic shock. Next we will focus on our three topics of interest individually: Initial Lactate Collection, Lactate Results, and Repeat Lactate Collection….
